logo
What Is The State Of Manufacturing & Supply Chain In 2025?

What Is The State Of Manufacturing & Supply Chain In 2025?

Forbes30-04-2025
Fictiv's 2025 State of Manufacturing & Supply Chain Report
This month, I'm excited to share the results of Fictiv's 10th Annual State of Manufacturing & Supply Chain Report. Every year, we survey hundreds of supply chain and manufacturing leaders across multiple industries to understand their perspectives, challenges, and predictions for 2025. I'm especially excited to dive into the broader supply chain results, particularly in a year marked by massive tariff and trade disruptions.
Our first findings concern business uncertainty. With the shift in the U.S. President's trade policies, almost 100% say they're concerned that trade wars are likely to escalate in the next few years (clearly demonstrated by widespread global tariffs).
Key Findings
96% of manufacturing leaders report they're concerned about the impact of the U.S. President's trade policies.
93% believe trade wars will likely escalate in the next few years, whereas 42% are now 'very concerned' —a 6-point increase over 2024.
91% note that global tensions are being considered in their company's long-term supply chain strategy—a 5-point increase over 2024.
Growing global business uncertainty
Looking at this chart, it's clear senior leaders are concerned about tariffs, particularly the impacts on costs and profitability, as well as global business. As a result, many are planning to increase manufacturing in the U.S.
The next key finding is around accelerating supply chain disruptions. Across the board, executives are saying they need to accelerate how they manage their supply chain. Two-thirds or 68% said that onshoring is a key priority this year for their teams.
Key Findings
68% of leaders prioritize onshoring as a key supply chain strategy in 2025, especially in industries needing complex parts at scale, like MedTech, clean energy, and EVs.
77% report a lack of resources (e.g., workforce, budget) severely limits their ability to manage their supply chains effectively (an increase over 2024).
52% of manufacturing leaders identify supplier quality, reliability, and compliance as significant challenges.
Accelerating supply chain disruptions
On the flip side, three-quarters, or 77%, say they lack the resources to effectively manage their supply chain as it is today. This is difficult given that leaders also say they want to onshore their supply chain. If supply chain resources are already limited, moving back to the U.S. will be a challenge.
50% are also saying that quality and reliability are significant challenges. Some are running well-performing supply chains, while another half are running inadequate supply chains.
Our third major finding is around scaling production. In my opinion, this has been the most difficult it's ever been. What you see here is 91% say they're facing barriers to innovation. In other words, they're struggling to find high-quality supply chain partners to do low-volume builds.
Key Findings
91% of manufacturing and supply chain leaders face barriers to product innovation and introduction, with nearly half struggling to source fast, high-quality solutions for low-volume builds.
86% report sourcing parts and materials takes time away from initiatives like new product innovation and introduction, making it increasingly difficult to move into and scale production.
90% of leaders consistently report that digital manufacturing platforms are an essential service for production (up from 86% in 2024).
Scaling production more difficult than ever
Secondly, almost 90% are saying that all the work required to source parts is taking away from innovation. In other words, you're launching a new product, and sourcing has become the bottleneck, the long pole on the tent. This makes driving innovation to build electric vehicles, rockets, and surgical equipment incredibly difficult—stalling the innovations of tomorrow.
In the 10 years we've been doing this report, we've consistently seen this trend. Executives are looking to digitize supply chains. This continues to be a key focus area and it's even up from the 86% that we saw last year. So my takeaway is that for teams that are scaling new products, and moving into production, you have to think about this as another phase of development. You have development that happens by building prototype one. Getting it in the market is the next and most difficult step.
Key Findings
95% report weather and extreme climate events are impacting their supply chain strategy in 2025.
91% now have sustainability initiatives and governance in place to help drive sustainability goals.
52% believe nearshoring and onshoring strategies are critical to supporting sustainability efforts.
Sustainability takes hold
The fourth finding centers around sustainability. This continues to be a major focus for our audience. As we know at the macro level, we've seen massive fires in California, floods and tsunamis globally, and hurricanes. These weather and extreme climate events are impacting supply chains around the world, and no industry is protected.
It's heartening to see that 91% now have sustainability initiatives and some type of governance in place, an increase from previous years. ESG has been a clear focus area for many executives and supply chain teams. However, this year, with 91% saying they have actual governance in place to do a triple bottom line, that's really encouraging to me. We're seeing sustainability as a large driver and metric for consideration in supply chains.
And lastly, nearshoring and onshoring are critical to supporting sustainability efforts. So nearshoring might not necessarily be a pure climate or sustainability play. There are other factors like economics, and geopolitical factors in play here. We thought this was an interesting takeaway. It's not just about reducing the carbon emissions by being closer to your customer, there are multiple considerations when nearshoring but excited to see this continue to be top of mind in our 10th Annual State of Manufacturing and Supply Chain Report.
And you can't have a report on the state of manufacturing in 2025 without AI. AI is the top trend shaping their long-term strategy, whether it's the latest, greatest LLMs or looking at augmenting human tasks, AI is at the forefront of our customers' minds.
Key Findings
87% of leaders report advanced levels of maturity with their company's AI implementations.
94% use AI for manufacturing and supply chain operations, such as inventory management and product design.
56% of Manufacturing and supply chain leaders identify AI as the leading trend shaping their long-term strategy, with economic headwinds following at 53%.
AI advances
Also, 87% report advanced levels of maturity in implementing AI. Almost 100% say their teams are getting better at using it for day-to-day tasks. I personally use it every single day, and I encourage all of our employees, partners, and customers to look at the ways that AI can help bring efficiencies to their work.
94% are saying that AI for manufacturing and supply chain operations is their main implementation, whether it's inventory management, product design, research, or supplier development. One of the best implementations that I saw was all around SCARS, so Corrective Action Reports and using it to help automate the process of managing supply chains. There are a lot of great applications and agentic products out there, and I would really encourage you to look at this to streamline your operations. If you don't do it, your competition will.
I think that while AI is here and will cause a lot of disruption, I think there are multiple factors to consider. So make sure you're figuring out how to implement it, implement it well, and use it daily, but it's not necessarily the silver bullet to solve all supply chain challenges.
Here are a few useful takeaways from the report for your consideration:
To download the full report, please go here. You can also watch an in-depth webinar discussion with Fictiv's General Managers of China, India, Mexico, and the U.S.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Vizient Reserve Program Expands Supply Assurance to Include IV Fluids in Collaboration With Baxter
Vizient Reserve Program Expands Supply Assurance to Include IV Fluids in Collaboration With Baxter

Yahoo

time2 days ago

  • Yahoo

Vizient Reserve Program Expands Supply Assurance to Include IV Fluids in Collaboration With Baxter

IRVING, Texas, July 23, 2025--(BUSINESS WIRE)--Vizient® announced today the expansion of the Vizient Reserve Program to include IV fluids through a strategic partnership with Baxter, a leading global medtech company, to help ensure reliable access to these critical products during times of supply disruption. The program provides participating healthcare organizations with dedicated, on-demand manufacturer inventory, warehoused in the U.S., along with comprehensive support to help safeguard continuity of care. The expansion of Vizient Reserve to include IV fluids reflects a strategic collaboration with Baxter to improve supply assurance within the healthcare supply chain and comes less than a year after Hurricane Helene hit the east coast, temporarily disrupting supply of this critical product. IV fluids—a uniquely complex category due to their essential nature, high utilization, and complex manufacturing requirements—are foundational to patient care. While Baxter's U.S. IV fluids production levels have been restored since the hurricane, the partnership between Vizient and Baxter reflects a deliberate, long-term strategy to promote resiliency and help healthcare providers prepare for and manage the pressures that natural disasters and increased demand have put on the supply of this critical healthcare category. "IV fluids are among the most relied upon therapies in healthcare. We've created a scalable, cost-effective reserve model that enhances resiliency and transparency across the supply chain," said Dan Kistner, senior vice president and general manager, category management & strategic programs, Vizient. "This approach builds on the success of our NES Reserve program in the pharmaceutical space, further demonstrating how Vizient is rethinking traditional sourcing strategies with proactive, purpose-built solutions designed to mitigate supply disruptions and ensure continuity of care." With comprehensive inventory management, transparent reporting and dedicated logistics, the program offers a flexible structure to enable access during supply disruptions and support continuity of care. "At Baxter, we are actively committed to supporting hospitals and health systems navigate any threat to supply continuity," said Cecilia Soriano, global president of Baxter's infusion therapies and technologies business. "Baxter and Vizient's shared commitment to enabling access to life-sustaining therapies is at the heart of this initiative, and we're honored to support Vizient clients in their efforts to build greater supply resilience." The new program builds on the success of Vizient Novaplus Enhanced Supply (NES) Reserve, which provides up to six months of additional dedicated manufacturer inventory for essential medications, and expands the breadth of products available through it—including the first-ever medical-surgery product codes. Since its inception, NES Reserve has fulfilled more than 45,000 requests from over 1,700 facilities, totaling more than 5 million additional units of essential medications. Learn more about IV fluids in the Vizient Reserve Program. About Vizient, Inc. Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company, serves more than 65% of the nation's acute care providers, including 97% of the nation's academic medical centers, and more than 35% of the non-acute market. The Vizient contract portfolio represents $140 billion in annual purchasing volume enabling the delivery of cost-effective, high-value care. With its acquisition of Kaufman Hall in 2024, Vizient expanded its advisory services to help providers achieve financial, strategic, clinical and operational excellence. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at View source version on Contacts Media ContactNancy Matocha(972)

Headquartered in Staunton, Cadence Inc. celebrates its 40th anniversary
Headquartered in Staunton, Cadence Inc. celebrates its 40th anniversary

Yahoo

time3 days ago

  • Yahoo

Headquartered in Staunton, Cadence Inc. celebrates its 40th anniversary

Cadence Inc., a leading provider of contract manufacturing solutions for the MedTech and Pharma industries, celebrates its 40th anniversary in 2025, according to a press release announcement from the company. Established in July 1985 by engineer Martin Lightsey, Cadence has grown into a vertically integrated global partner, committed to advancing patient outcomes in collaboration with its OEM customers, the release said. The company offers comprehensive contract manufacturing services from initial design and development through manufacturing and full supply chain management of medical devices worldwide. 'Forty years ago, Cadence began with a simple yet powerful vision to provide custom solutions to OEMs through engineering and innovation,' said Cadence's President and CEO Rob Werge. 'Today, we are a highly differentiated provider to MedTech and Pharma OEMs because of our commitment to supporting our customers' success; however, nothing would be possible without the great team of people at Cadence.' The company now operates eight facilities across the U.S. and Costa Rica and employs approximately 800 people with its corporate headquarters located in Staunton, Virginia. Cadence delivers a wide range of capabilities from finished device assembly and packaging to nearshore operations, CNC grinding, precision machining, metal stamping, deep draw stamping, metal injection molding (MIM), laser processing and plastic injection molding. These capabilities support a diverse set of surgical end markets, including robotic-assisted surgery (RAS) and minimally invasive surgery (MIS), while also driving deeper collaboration into drug delivery and diagnostics with key customers. Through this vertically integrated approach, it can simplify and consolidate supply chains, providing efficient, cost-effective solutions that help bring life-changing medical technologies to market faster, the release said. "As part of our commitment to continuous improvement, Cadence has strengthened our New Product Introduction (NPI) process by building a world-class program management team and enhancing our manufacturability (DFM) expertise," the company said in the release. In addition, the company has made investments in its manufacturing footprint — expanding operations and upgrading equipment — to meet growing demand and support increasing product complexity. In early 2025, Cadence unveiled a refreshed brand to honor its rich heritage while reflecting its evolution as a trusted leader in MedTech manufacturing, the company said in the release. "As we enter our fifth decade, Cadence remains committed to delivering innovative solutions that improve patient outcomes and support the development of next-generation medical technologies." 'We're proud of the journey that brought us here and even more excited about the future we are building,' said Werge. More: After 39 years, architectural firm Frazier Associates closes in Staunton More: Augusta school board candidate charged with misdemeanor assault Monique Calello is a reporter at The News Leader. Story ideas always welcome. Connect with her at mcalello@ Support local journalism and subscribe to us at This article originally appeared on Staunton News Leader: Headquartered in Staunton, Cadence celebrates its 40th anniversary Solve the daily Crossword

Eased Tariff Impact Fails To Lift Abbott As Outlook Cut Disappoints Investors
Eased Tariff Impact Fails To Lift Abbott As Outlook Cut Disappoints Investors

Yahoo

time17-07-2025

  • Yahoo

Eased Tariff Impact Fails To Lift Abbott As Outlook Cut Disappoints Investors

Abbott Laboratories (NYSE:ABT) reported better-than-expected sales and profits in the second quarter, but the stock still plummeted nearly 10% after management dialed back earnings and growth projections for the rest of the year. The company reported second-quarter sales of $11.14 billion, beating the consensus of $11.07 billion. Second-quarter sales increased 7.4% on a reported basis, 6.9% on an organic basis, or 7.5% when excluding COVID-19 testing-related U.S. MedTech giant reported adjusted earnings of $1.26, beating the consensus of $1.25, and within the management guidance of $1.23-$1.27. 'Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline,' said Robert B. Ford, chairman and chief executive officer, Abbott. 'We see this momentum carrying into 2026.' Medical Devices sales increased 13.4% on a reported basis and 12.2% on an organic basis to $5.37 billion. Sales growth in the quarter was led by double-digit growth in Diabetes Care, Heart Failure, Structural Heart, and Electrophysiology. Several products contributed to the performance, including FreeStyle Libre, Navitor, TriClip, and AVEIR. In Diabetes Care, sales of continuous glucose monitors were $1.9 billion and grew 21.4% on a reported basis and 19.6% organically. Worldwide Nutrition sales increased 2.9% (+3.4% on an organic basis) to $2.21 billion. View more earnings on ABT Growth in the quarter was led by Adult Nutrition, where global sales increased 6.1% (+6.6% on an organic basis), led by strong growth of Ensure and Glucerna. Global Diagnostics sales decreased 1% (-1.4% on an organic basis) and increased 0.8% when excluding COVID-19 testing-related sales. The year-over-year decline in COVID-19 testing-related sales and volume-based procurement programs in China impacted diagnostics sales growth. COVID-19 testing-related sales were $55 million in the quarter, compared to $102 million a year ago. Established Pharmaceuticals sales increased 6.9% (+7.7% on an organic basis) to $1.38 billion. Abbott's reported operating margin of 18.4%, with an adjusted operating margin of 22.9%, which reflects a 100 basis point increase. Guidance Abbott narrowed full-year 2025 adjusted earnings guidance from $5.05-$5.25 per share to $5.10-$5.20 per share compared to the consensus of $5.16. The company expects organic sales growth of 7.5%-8.0% compared to prior guidance of 7.5%-8.5%, or 6.0% to 7.0% when including COVID-19 testing-related sales. Abbott forecasts an adjusted operating margin of approximately 23.5% of sales, down from prior guidance of 23.5%- 24.0%. Abbott expected third-quarter 2025 adjusted earnings of $1.28-$1.32 per share, compared to the consensus of $1.34 per share. During the earnings conference call, an Abbott executive addressed the impact of tariffs, reporting that the estimated headwind has been revised down to $200 million for the year, lower than previous estimates. Price Action: ABT stock is trading lower by 8.00% to $121.21 at last check Thursday. Read Next:Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? ABBOTT LABORATORIES (ABT): Free Stock Analysis Report This article Eased Tariff Impact Fails To Lift Abbott As Outlook Cut Disappoints Investors originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store